09.10.2017 • News

Bayer Cedes Control of Covestro

(c) Covestro
(c) Covestro

Through the sale of an additional 6.9% of engineering plastics producer Covestro for €1 billion, Bayer has ceded control of its former group company known earlier as Bayer MaterialScience.

Under a control termination agreement that took effect from Sept. 30, Bayer will refrain from exercising certain voting rights at the Covestro annual general meeting, so that the plastics company will no longer be fully consolidated in the former parent’s consolidated financial statements.

Covestro will be reported as a discontinued operation in Bayer’s financial reporting for the third quarter of 2017. For continuing operations, Bayer’s key figures, including sales, EBITDA before special items, EBIT and core earnings per share, will be adjusted retrospectively to exclude Covestro’s contributions.

In addition, all assets and liabilities allocated to Covestro will not be included in Bayer’s statement of financial position as of Sept. 30, 2017. The remaining Covestro interest will be carried at the current market value, and, from Oct. 1, 2017, accounted for using the equity method.

With the share sale, Bayer has taken a major step toward its goal of a full separation from Covestro in the medium term, CEO Werner Baumann said.  The former parent company’s stakeholding is now only 24.6%, but the Bayer Pension Trust continues to hold 8.9%.

Buyers of the Covestro shares have agreed to a lock-up arrangement that stipulated they may not be sold before Dec. 11, 2017 at the earliest. Bayer said it will retain economic exposure to the price of these shares until at least the same date.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.